Psyence Biomedical Ltd. Common Shares (PBM) Dividend History

Company News

• US Stocks To Open Lower As Traders Brace For 'Triple Witching' Hour: Analyst Says End Of The Year Recovery 'Would Not Surprise Anyone'

  U.S. stock futures declined ahead of the 'Triple Witching' hour, with the market expected to see the expiry of about $6.6 trillion options. Analysts have mixed views on the market's recovery by the end of the year.

  Benzinga

  Featured Companies: BB CCL FDX HUMA NKE QQQ SPY
• Psyence Biomedical Announces Closing of Previously Announced Acquisition of Psyence Group's Stake in PsyLabs

  Psyence Biomedical has acquired an 11.13% stake in PsyLabs, a company focused on the cultivation and production of psychedelic active pharmaceutical ingredients. The acquisition is expected to benefit Psyence Biomedical's pipeline of psychedelic-based therapeutics.

  Benzinga
• Psyence Biomed Enters into Agreement to Acquire Stake in PsyLabs

  Psyence Biomed has entered into an agreement to acquire an 11.13% stake in PsyLabs, a company focused on the production of psychedelic active pharmaceutical ingredients. This acquisition will strengthen Psyence Biomed's relationship with PsyLabs and provide access to state-of-the-art cultivation and production capabilities.

  Benzinga
• Psyence Biomed Announces the Signing of a Conditional Binding Term Sheet for the Acquisition of Psilocybin-Based Drug Developer Clairvoyant

  Psyence Biomed has signed a conditional binding term sheet to acquire Clairvoyant, a clinical-stage developer of psilocybin-based therapeutics. Clairvoyant is currently executing a Phase IIb clinical trial evaluating a synthetic psilocybin candidate as a potential treatment for Alcohol Use Disorder (AUD), with topline data expected in early 2025.

  Benzinga
• Psyence Biomed Announces Registration Statement on Form F-1 for Up to $25 Million Equity Line of Credit with White Lion Capital, LLC, Declared Effective by SEC

  Psyence Biomed, a biotechnology company focused on developing botanical psilocybin-based psychedelic medicine, announced that its $25 million equity line of credit with White Lion Capital has been declared effective by the SEC. This provides a potential funding source as the company prepares to initiate a Phase IIb clinical trial for a psilocybin-based treatment for Adjustment Disorder in Palliative Care.

  GlobeNewswire Inc.